Jazz Pharmaceuticals Completes Biologics License Application for Zanidatamab for HER2-Positive Metastatic Biliary Tract Cancer
Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States.
Approval would mark first HER2-targeted therapy for biliary tract cancer in the United States.
